BMS receives positive CHMP opinion recommending Opdivo for head and neck cancer

Opdivo already approved by the EC for six indications in four distinct tumour types.

“Nearly half of all patients with SCCHN relapse within 2 years of treatment and limited advancements have been made in the last 10 years, underscoring the critical need for new treatment options for patients affected by this devastating illness,” commented Emmanuel Blin, senior vice president and chief strategy officer, BMS. “We are very pleased that the CHMP has recommended the approval of Opdivo for adults with SCCHN who have progressed on or after platinum-based therapy and look forward to working with the EC as they review this treatment as a potential option for patients in the EU.”

The CHMP adopted a positive opinion based on results from CheckMate -141, a pivotal Phase III open-label, randomized trial, that evaluated the overall survival (OS) of Opdivo in previously treated patients with SCCHN following platinum-based therapy compared to investigator’s choice of therapy (methotrexate, docetaxel, or cetuximab) in the adjuvant, primary, recurrent or metastatic setting. Based on a planned interim analysis, this trial was stopped early in January 2016 because an assessment conducted by the independent Data Monitoring Committee concluded the study met its primary endpoint of OS superiority in patients receiving Opdivo compared to investigator’s choice of therapy. Overall survival data from CheckMate -141 were first presented at the 2016 Annual Meeting of the American Association for Cancer Research. The safety profile of Opdivo in CheckMate -141 was consistent with prior studies in other tumours.